Vol. 39 No. 2 (2022): ABRIL
Clinical Case

Rothia mucilaginosa pneumonia in an immunocompromised patient after kidney transplant

Alejandro Kral
HOSPITAL CARLOS VAN BUREN
Erika Rubilar
Unidad de Infectología, Servicio de Medicina, Hospital del Salvador Departamento Medicina Oriente, Facultad de Medicina, Universidad de Chile.
María Victoria Moreno
Laboratorio Clínico Hospital del Salvador
Andrés Soto
Unidad de Infectología, Servicio de Medicina, Hospital del Salvador Departamento Medicina Oriente, Facultad de Medicina, Universidad de Chile.

Published 2022-06-08

How to Cite

1.
Kral A, Rubilar E, Moreno MV, Soto A. Rothia mucilaginosa pneumonia in an immunocompromised patient after kidney transplant. Rev. Chilena. Infectol. [Internet]. 2022 Jun. 8 [cited 2026 Apr. 30];39(2). Available from: https://revinf.cl/index.php/revinf/article/view/1218

Abstract

Rothia mucilaginosa is a bacterium derived from the upper respiratory tract microbiota, which is rarely associated with infections in immunocompromised patients suffering chronic lung diseases, mainly pneumonia and bacteremia. Its treatment is generally based on the use of b-lactams. The case study of a kidney transplant patient using immunosuppressive drugs, who developed a disseminated Cryptococcus neoformans infection, is described. After starting antifungal therapy, he presented with fever, appearance of new radiological    infiltrates and acute respiratory failure, demonstrating a positive culture for R. mucilaginosa in a study with bronchoalveolar lavage, ruling out other etiologies. He evolved favorably after the use of meropenem, with good clinical response and resolution of radiological infiltrates.